Thumbnail Image
Publication

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre, S
; 
Niccoli, P
; 
Castellano, D
; ; 
Hammel, P
; 
Raoul, J
; 
Vinik, A
; 
Van Cutsem, E
; 
Bang, Y
; 
Lee, S
... show 10 more
Citations
Altmetric:
Abstract
In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.
Authors
Faivre, S
Niccoli, P
Castellano, D
Valle, Juan W
Hammel, P
Raoul, J
Vinik, A
Van Cutsem, E
Bang, Y
Lee, S
Borbath, I
Lombard-Bohas, C
Metrakos, P
Smith, D
Chen, J
Ruszniewski, P
Seitz, J
Patyna, S
Lu, D
Ishak, K
Raymond, E
Affiliation
Medical Oncology and Gastroenterology Department, Service Inter-Hospitalier de Cancerologie, Hopital Beaujon, Clichy, France
Description
Date
2016-11-10
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Main article
Adobe PDF, 312.46 KB
Keywords
Type
Article
Citation
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. 2016, Ann Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620110
Embedded videos